In the News

Advanced Age Is Associated With Catatonia in Critical Illness: Results From the Delirium and Catatonia Prospective Cohort Investigation

Catatonia, characterized by motor, behavioral and affective abnormalities, frequently co-occurs with delirium during critical illness. Advanced age is a known risk factor for development of delirium. However, the association between age and catatonia has not been described. We aim to describe the occurrence of catatonia, delirium, and coma by age group in a critically ill, adult population. First Author: Vanderbilt Medical Student Jennifer Connell Senior Author: Jo Ellen Wilson, MD, MPH 

Warren paper examines dysfunction in dopamine system, influence on depression in older adults

Warren D. Taylor, M.D., MHSc, James G Blakemore Professor of Psychiatry, served as lead author of a new publication proposing how dysfunction in the dopamine system may influence depression in older adults. This may influence risk for depression but also serve as a new target for treatment.  The manuscripts provides the rationale for a current multi-site study being conducted at Vanderbilt examining the effect of levodopa (Sinemet) on late-life depression. The paper appears in the journal Molecular Psychiatry. 

Study to explore treatment for older adults with depression

Older adults with depression face a unique obstacle — dealing with both a mental illness and the challenges that come along with aging. Currently, there are no treatments on the market targeting depression in this specific group. The Department of Psychiatry and Behavioral Sciences has received a grant to study Sinemet, which may change that. Sinemet, a brand name for the drug levodopa, has historically treated Parkinson’s disease, a brain disorder characterized by injury to dopamine-producing neurons.

Study links ADHD pharmacotherapy and retention rates for substance use disorder treatment

Kristopher Kast, MD, assistant professor in the Department of Psychiatry and Behavioral Sciences and clinical director of Vanderbilt’s Addiction Consult Service, has discovered a strong association between attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy and retention rates for substance use disorder (SUD) treatment. The findings were reported in the Journal of Clinical Psychiatry.